




RealRate

PHARMACEUTICAL 2015

Sucampo Pharmaceuticals Inc
Rank 125 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sucampo Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sucampo Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Sucampo Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 296%, being 42% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	122,324
Cost of Goods Sold	0
Intangible Assets	151
Liabilities, Current	33,810
Liabilities, Non-Current	1,936
Other Assets	18,336
Other Compr. Net Income	-1,336
Other Expenses	50,428
Other Liabilities	23,516
Other Net Income	-98
Other Revenues	115,450
Property and Equipment	763
Research and Development	20,566
Selling, General and Administrative Expense	31,230

Output Variable	Value in 1000 USD
Assets	141,574
Liabilities	59,262
Expenses	102,224
Revenues	115,450
Stockholders Equity	82,312
Net Income	13,128
Comprehensive Net Income	12,460
BaseVar	209,972
ECR before Limited Liability	191%
Economic Capital Ratio	296%